Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard of care for advanced non-small-cell lung cancer (NSCLC) patients. However. most patients will eventually develop resistance. For EGFR-TKI resistance mediated by MET amplification. https://www.secondgearwncers.shop/product-category/footwear-womens-shoes/
Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
Internet 2 hours 44 minutes ago waihnbqcv1u5
Web Directory Categories
Web Directory Search
New Site Listings